Andelyn Biosciences is a pioneering gene therapy organization born out of Nationwide Children's Hospital that helps clients innovate and produce new gene therapies in order to transform, extend and save lives.
Andelyn has partnered in over 60+ US, EU and ROW clinical trials, including the innovation of Zolgensma – the first FDA approved gene therapy for Spinal Muscular Atrophy. The name “Andelyn” was chosen to pay tribute to two patients that participated in pivotal clinical trials for Zolgensma. Their combined names serve as a reminder that while Andelyn is a biotech business, the patient is always first.
Andelyn Biosciences supports clients from preclinical through Phase 3 trials. A 200,000 square-foot late stage and commercial manufacturing facility will be operational in mid-2022, allowing Andelyn to be a full spectrum Gene Therapy partner.
Their capabilities include Viral Vector process and analytical development, small to large scale GMP manufacturing, Fill/Finish and quality release testing. The company also offers plasmid manufacturing services and vector development (GMP, Tox grade and R&D).
Their experts can help you take through all stages of making your ideas reality, reducing the need and time for tech transfers. They are your trusted partner for accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients.